Clinical Trial Update: First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal Degeneration [EARLY_Phase 1]

View source ↗

Summary

This notice reports a first-in-human, dose-escalation Phase 1 trial of AXV-101 for Bardet-Biedl syndrome type 1–related retinal degeneration; the study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bardet-biedl Syndrome Type
• Retinal Degeneration

Drugs mentioned

• AXV-101

Snippet

Sponsor: Axovia Therapeutics | Conditions: Bardet-Biedl Syndrome 1, Retinal Degeneration | EARLY_Phase 1 | Status: NOT_YET_RECRUITING